Nexus Pharmaceuticals is proud to announce the approval of a patent covering EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine. The patent, issued by
the United States Patent and Trademark Office (USPTO), represents our commitment to bringing innovation and patient safety to medicine.
 
Read our full press release here.

Applicable Patent Notice

This list is current as of October 7th, 2021.

The information is not intended to be exhaustive, and is not a representation that the patents listed are the only intellectual property owned by Nexus and applicable to the associated product.

Our EMERPHED® product and use are covered by patents: 

  • 11,090,278
  • Other patents pending

EPH-138-v1